| Range: |
|
Over the next three years Ascent expects to release over 20 new generic drugs including all the major patent expiring medicines with total PBS value of over $750 million per annum. |
|
|
|
|
|
|
| |
|
Ascent's range extends beyond generic drugs to key pharmacy consumer health lines such as skincare, analgesics (pain relief), hay fever and vitamin supplements. The Company expects to release a number of innovative products and brand concepts over the next three years aligning the business with key growth segments within the pharmacy retail offer. |
| |
|
|
| Value: |
|
In conjunction with breadth of range, the Company has developed supply partnerships that ensure its range of products are cost effective while providing all stakeholders in the supply chain – manufacturers, wholesalers, pharmacists and consumers – competitive and sustainable value propositions.
|
| |
|
|
| |
|
The Ascent dermatology offer has positioned the Company in a strong position to build further medical specialty ranges. A number of opportunities are currently being reviewed with specialist manufacturers to create similar high value offerings for the Australian and Asian markets. |
| |
|
|
| Appeal: |
|
Ascent is strongly committed to a culture of innovation and differentiation increasing the appeal for our customers and consumers of our products and brands. In a highly competitive generic market the Company views innovation and a culture of collaboration as a competitive advantage. This culture is driven by emphasis on building and maintaining relationships that create long term value for all. |
| |
|
|
| |
|
Ascent recognises that a large part of the appeal to customers lies in its people. Ascent's management and sales representatives are an experienced group with backgrounds in retail pharmacy, consumer health and wholesale distribution. This team will lead the Company's sales and marketing operations into further expansion in the years to come. |